Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CHRM2 | P08172 | 1/20 | 0.43 |
| ▸ | CARM1 | Q86X55 | 4/20 | 0.41 |
| ▸ | PRMT6 | Q96LA8 | 3/20 | 0.41 |
| ▸ | PRMT8 | Q9NR22 | 1/20 | 0.41 |
| ▸ | HRH3 | Q9Y5N1 | 3/20 | 0.40 |
| ▸ | ACHE | P22303 | 1/20 | 0.40 |
| ▸ | OPRD1 | P41143 | 1/20 | 0.38 |
| ▸ | ADRB2 | P07550 | 1/20 | 0.36 |
| ▸ | CHRM3 | P20309 | 1/20 | 0.36 |
| ▸ | DRD4 | P21917 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL768818 | 0.86 | CHRM2 (0.42) | CHRM2CARM1PRMT6PRMT8HRH3 | |
| SCHEMBL28524732 | 0.84 | CHRM2 (0.51) | CHRM2HRH3ACHEOPRD1ADRB2 | |
| SCHEMBL28521336 | 0.84 | CHRM2 (0.49) | CHRM2HRH3ACHEOPRD1ADRB2 | |
| SCHEMBL768110 | 0.81 | OPRD1 (0.44) | CHRM2CARM1PRMT6PRMT8ACHE | |
| SCHEMBL28953805 | 0.80 | CHRM2 (0.67) | CHRM2ACHEOPRD1 | |
| SCHEMBL381835 | 0.80 | CHRM2 (0.66) | CHRM2ADRB2CHRM3 | |
| SCHEMBL768103 | 0.79 | HRH3 (0.41) | CHRM2CARM1PRMT6HRH3CHRM3 | |
| SCHEMBL768609 | 0.79 | CARM1 (0.52) | CARM1PRMT6PRMT8 | |
| SCHEMBL769143 | 0.78 | CHRM2 (0.40) | CHRM2CARM1PRMT6PRMT8HRH3 | |
| SCHEMBL768953 | 0.78 | HRH3 (0.42) | CHRM2HRH3CHRM3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20120071467-A1 | AMIDE DERIVATIVE | DAIICHI SANKYO COMPANY, LIMITED (JP) | 2012-03-22 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120071467-A1 | AMIDE DERIVATIVE | CHRM3, CHRM2, TACR2 | CHRM2 2/4885CARM1 1411/4885PRMT6 1142/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.